Universal Beteiligungs und Servicegesellschaft mbH Invests $3.49 Million in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,637 shares of the medical research company's stock, valued at approximately $3,494,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Blue Trust Inc. lifted its stake in shares of Bio-Rad Laboratories by 7.2% in the fourth quarter. Blue Trust Inc. now owns 1,132 shares of the medical research company's stock valued at $379,000 after purchasing an additional 76 shares during the period. Tokio Marine Asset Management Co. Ltd. lifted its position in shares of Bio-Rad Laboratories by 3.9% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company's stock valued at $296,000 after acquiring an additional 34 shares during the period. DAVENPORT & Co LLC boosted its stake in shares of Bio-Rad Laboratories by 48.8% during the 4th quarter. DAVENPORT & Co LLC now owns 84,677 shares of the medical research company's stock worth $27,817,000 after acquiring an additional 27,780 shares in the last quarter. Mather Group LLC. boosted its stake in shares of Bio-Rad Laboratories by 172.8% during the 4th quarter. Mather Group LLC. now owns 461 shares of the medical research company's stock worth $151,000 after acquiring an additional 292 shares in the last quarter. Finally, Retirement Systems of Alabama grew its holdings in shares of Bio-Rad Laboratories by 0.7% in the 4th quarter. Retirement Systems of Alabama now owns 23,413 shares of the medical research company's stock worth $7,691,000 after acquiring an additional 153 shares during the period. Institutional investors and hedge funds own 65.24% of the company's stock.

Bio-Rad Laboratories Trading Up 2.1%

Shares of NYSE BIO traded up $4.59 during midday trading on Tuesday, reaching $221.15. 374,091 shares of the stock were exchanged, compared to its average volume of 327,596. The stock has a 50 day moving average price of $238.38 and a 200-day moving average price of $287.87. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $6.02 billion, a P/E ratio of -3.40 and a beta of 1.00. Bio-Rad Laboratories, Inc. has a 52-week low of $211.43 and a 52-week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share for the quarter, topping the consensus estimate of $1.73 by $0.81. The business had revenue of $585.40 million for the quarter, compared to analyst estimates of $573.01 million. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The company's revenue was down 4.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.30 EPS. Equities research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BIO has been the topic of a number of research analyst reports. UBS Group decreased their target price on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Wells Fargo & Company decreased their price objective on shares of Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Wall Street Zen upgraded shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a report on Saturday. Citigroup lowered their price target on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Finally, Royal Bank of Canada dropped their price objective on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Bio-Rad Laboratories has an average rating of "Moderate Buy" and an average price target of $327.40.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.